This new appointment bolsters CJ’s global food business with the new CMO’s expertise in global FMCG marketing

SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ — CJ Foods, a business unit of South Korea-based CJ CheilJedang, announced that it has appointed Stephan Czypionka, former Global Vice President of Marketing Performance at The Coca-Cola Company, as the new global Chief Marketing Officer (CMO).

Stephan Czypionka, Global CMO at CJ Foods

With a distinguished career spanning over two decades, Czypionka brings a wealth of marketing expertise to CJ’s rapidly expanding global food business.

Czypionka’s extensive marketing career began in 2000 with Orange Austria, and he subsequently joined The Coca-Cola Company in 2005, where he held various marketing leadership roles across diverse markets in Asia, Africa, Europe, and Latin America.

"I am excited to have Stephan as part of our global leadership team. His extensive marketing experience in marketing strategy, brand building, campaign execution and marketing performance management will be instrumental in enhancing our global brand building and marketing capabilities. I look forward to the impact that he will have working with our regional marketing teams," said Minsok Pak, CEO of CJ Foods.

Before joining CJ, Czypionka was the Global Vice President of Marketing Performance at The Coca-Cola Company. In this role, he redefined the company’s marketing performance metrics in over 250 markets. By introducing a globally standardized, industry-leading measurement suite, he established a more data-driven and effective global marketing organization. Czypionka has also proven himself an insightful strategist by winning back major markets during his multiple leadership roles worldwide. Notably, in the Philippines, he revitalized the brands by reconnecting with a key demographic, orchestrating a successful turnaround, ultimately making it one of the world’s fastest-growing markets.

Czypionka graduated from University of Vienna in Austria and earned his MBA from Polytechnic University of Madrid in Spain.

About CJ Foods

CJ Foods, a business unit of CJ CheilJedang, is a global food company delivering a variety of products ranging from foodstuffs and frozen/chilled foods to appetizers. As the largest food company in Korea with global sales of 11.1 trillion KRW in 2022, CJ Foods is now leading the globalization of Korean food with its fast-growing bibigo brand. Under bibigo, CJ currently focuses on seven delicious Global Strategic Products of K-food, including Mandu (Korean-style dumpling), chicken, processed rice, Korean sauce, Kimchi, Gim (seaweed), and roll to global consumers. The company operates over 60 sites in multiple regions worldwide including South Korea, the U.S. (Schwan’s Company), China, Japan, Southeast Asia, Europe, and Oceania.

For more information, visit https://www.cj.co.kr/en/about/business/food

About CJ CheilJedang

CJ CheilJedang is a South Korea-based food & bio company operating globally. Founded in 1953 as the first Korean sugar manufacturer, it is now a leading global food player with brands such as bibigo. It also provides advanced bio products including feed and food additives made by its cutting-edge, fermentation-based bioengineering technologies. The company recorded sales of 30 trillion KRW in 2022. CJ CheilJedang is part of CJ Group, an international company in the fields of Food & Food Services, Bio & Pharma, Entertainment & Media, and Retail & Logistics.

For more information, visit https://www.cj.co.kr/en

Source : CJ Foods Appoints Stephan Czypionka as Global Chief Marketing Officer

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

YANGZHOU, China, Oct. 31, 2023 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced today the establishment of a subsidiary, Hainan Ruiying Technology Co., Ltd. ("Ruiying Technology"), in the Hainan Free Trade Port Boao Hope City ("Hope City") in Qionghai City, Hainan Province.

With our newly developed company, Ruiying Technology, we intend to leverage the exceptional policy advantages offered by Hope City, with the aim of advancing the Chinese medical landscape by introducing cutting-edge patented pharmaceuticals, medical technologies and civilian household equipment from renowned markets like the United States, Japan, and Israel. The core focus of Ruiying Technology, which will serve as a trading and import-export company, will be in acting as a portal and facilitating the introduction of new medical technology, devices and equipment to the market, including state-of-the-art medical devices including hearing aids, ultrasonic earwax cleaners, and advanced blood glucose meters.

For the Company, the establishment of our subsidiary Ruiying Technology in Hope City holds strategic importance as it enables the Company to spearhead the introduction of advanced global technologies and esteemed brands into the Chinese market. Hope City’s progressive policies allow for the direct use and real-world data research of new drugs or medical devices that have been certified by the U.S. Food and Drug Administration ("U.S. FDA") or the European Union CE certification, and also enables simultaneous approval applications to the Hainan Provincial Medical Products Administration. We anticipate these policies should significantly shorten the approval time for new drugs or innovative medical devices, providing great convenience for patients. Hope City stands as the sole region within China to enjoy this remarkable privilege, positioning it as an unparalleled hub of medical and healthcare industries in China. As the parent company of Ruiying Technology, many products of the Company have obtained international CE certification, and some of them have also been registered with the U.S. FDA. We anticipate that the development of Ruiying Technology, along with the progressive policies available in Hope City, will expand the scope of MHUA’s product offerings in the future.

Moreover, Ruiying Technology is set to forge a close partnership with the Company’s subsidiary Hainan Guoxie Technology Group Co., Ltd. ("Hainan Guoxie"). While Ruiying Technology will focus on technology introduction, Hainan Guoxie will remain dedicated to the production and distribution of medical products and devices. We believe that this collaborative synergy ensures a seamless fusion of technology importation and localized production, reducing material costs and improving operational efficiency, culminating in MHUA’s provision of exceptional, high-quality medical products tailored to the Chinese market.

Mr. Yongjun Liu, Chairman of MHUA, commented: "We founded Ruiying Technology, a subsidiary of MHUA, to establish a professional medical product and technology import company in Hope City in China. Our goal is for Ruiying Technology to unlock opportunities and catalyze the development of China’s medical industry, and assist in propelling the advancement of domestic medical technology by providing Chinese patients with access to superlative medical services and products. We are committed to the comprehensive medical industrial park project and its construction, underscoring the indomitable spirit with which MHUA intends to leverage Hainan’s unique geographical advantages and harness the distinctive differentiators of Hainan as China’s vanguard free trade port. We believe these strategic endeavors will establish a solid foundation for the Company’s upcoming phase of continued growth and unwavering success."

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strip, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international "CE" certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for over 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania. For more information, please visit www.meihuamed.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company’s future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled "Risk Factors" in its annual report on Form 20-F, as amended, filed with the SEC on August 29, 2023, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Janice Wang
Wealth Financial Services LLC
Phone:
+86 13811768599
+1 628 283 9214
Email: services@wealthfsllc.com

Source : Meihua International Medical Technologies Co., Ltd. Establishes A Subsidiary Dedicated to Introducing International Patented Pharmaceuticals and Medical Device Technologies to China and Hainan Free Trade Port Boao Hope City

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Oct. 31, 2023 /PRNewswire/ — Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held in Singapore.

The Hello Tomorrow APAC Challenge is a prestigious annual competition where deep tech startups from the Asia-Pacific region exhibit their innovative solutions, rooted in advanced science and engineering, to address global challenges. Psylo was selected as the winner from over 200 contenders, securing an equity-free grant and sponsored trips to Singapore and Paris to participate in SLINGSHOT 2023 and the Hello Tomorrow Global challenges, respectively.

Leveraging its proprietary platform, Psylo is at the forefront of developing serotonergic agents with enhanced selectivity and efficacy. Their lead 100X series, a class of functionally selective 5-HT2A agonists, has shown promising antidepressant and neuroplasticity-promoting effects in preclinical studies.

"We are immensely honoured to have been selected as the winner of the Hello Tomorrow APAC Challenge," said Dr William Jorgensen, Psylo’s Director of Medicinal Chemistry and representative at the competition. "This recognition reflects the tireless efforts of our team and the transformative potential of our platform in revolutionising the treatment of CNS disorders."

Psylo’s Growing Presence in Asia

Psylo, headquartered in Australia with operations in the US, is now expanding its presence in Asia. This strategic growth is underscored by a recent sponsored research agreement with Daiichi Sankyo, one of the largest pharmaceutical companies in Japan and world leader in drug development. Under the terms of the agreement, Psylo will receive funding and support for developing psychiatric therapies based on its proprietary platform.

"We are eager to expand our presence in Asia," said Joshua Ismin, Psylo’s Chief Executive Officer. "Earlier this year we began building a team in the US to support our partnership with Daiichi Sankyo. This win at the Hello Tomorrow APAC Challenge further validates our global strategy."

Psylo’s Research Progress

Psylo is currently advancing four lead series of serotonergic agents with reduced side effects and optimised pharmacological profiles. The 100X series is the most advanced series showing substantial promise for clinical translation.

"The 100X series could represent a paradigm shift in psychiatry. This novel class of 5-HT2A agonists, which has shown promising antidepressant effects in preclinical studies and promotion of neuroplasticity, could redefine the treatment of depression and other CNS disorders," said Dr. Samuel Banister, Psylo’s Chief Scientific Officer. "Aligned with Psylo’s mission, our innovative approach aims to offer a safer and more effective alternative to traditional SSRI antidepressants and reduce suffering from neuropsychiatric and CNS disorders."

Psylo is planning to initiate the Investigational New Drug (IND)-enabling studies necessary for human clinical trials in early 2024.

About Psylo

Psylo is an Australian biotechnology start-up developing next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders. The company’s proprietary platform enables the discovery and development of serotonergic agents with improved selectivity and efficacy. Psylo is led by a team of experienced scientists and entrepreneurs with a proven track record in the pharmaceutical industry.

Links

Hello Tomorrow APAC Challenge: https://www.hello-tomorrow-apac.org/ Psylo announcement of sponsored research agreement with Daiichi Sankyo: https://www.prnewswire.com/news-releases/psylo-announces-sponsored-research-agreement-with-daiichi-sankyo-to-develop-non-hallucinogenic-psychiatric-therapies-301857884.html

Source : Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

MELBOURNE, Australia, Oct. 31, 2023 /PRNewswire/ — Hinen, a subsidiary of CE-LINK and an innovator in the energy storage industry, is thrilled to review a successful presence at the All-Energy Australia Exhibition. With a focus on cutting-edge products, Hinen’s exhibition left a lasting impression and received exceptional feedback.

After the exhibition

A star of the exhibition was the 5kW Single-phase Hybrid Inverter, an innovation that combines impressive features with an elegant design. With a remarkable DC/AC ratio of up to 190%, this inverter sets a new standard in efficiency. Its fanless design, enabling natural heat dissipation, garnered significant attention, emphasising Hinen’s commitment to performance.

Reactions and Recognition

The unique appearance and design of Hinen’s products resonated with the audience, positioning Hinen as a forward-thinking brand in the energy storage sector.

Although successful use cases weren’t showcased officially due to ongoing website updates, Hinen arranged systematic tests to demonstrate the robustness and performance. The positive reception has elevated Hinen’s presence in the Australian market. The brand’s reputation is expected to flourish based on the overall user experience.

Hinen’s product range aligns perfectly with market demands, including the 15 kW Single-Phase All-in-One Module and the 20 kW Three-phase All-in-One Module. Additionally, Hinen is developing 5 kW Single-phase Hybrid Inverters, a rarity in the market. With upcoming regulations in Victoria and NSW that will disconnect new homes from gas, the inverter will play a pivotal role as an intelligent, independent energy hub, managing PV generation, energy storage, and grid connectivity through a user-friendly app.

Furthermore, the integration of heat pumps with Hinen’s inverters is a significant development. The inverter pairs seamlessly with batteries, allowing homeowners to use their own batteries without a separate unit.

Opportunities for Collaboration

Hinen reminds dealers and installers that collaboration opportunities extend beyond the exhibition. The company is eager to connect with industry professionals, sharing product information and cooperation plans. Hinen’s commitment to innovation and excellence positions them as an ideal partner for those looking to offer top-of-the-line energy solutions.

A Vision for the Future

Hinen General Manager, William Peng, shared his enthusiasm, stating, "Our experience has been remarkable. The warm reception and feedback affirmed our commitment to pushing the boundaries of energy storage. We look forward to building stronger connections in the Australian market."

For more information, contact William Peng on +61 466 068 058 or williampeng@hinen.com

Source : Hinen Celebrates Success at All-Energy Australia Exhibition: A Glimpse into the Future of Energy Storage

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Oct. 31, 2023 /PRNewswire/ — Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, is proud to announce the development of a new gene-editing method that significantly shortens back cross procedures from 4-5 years to just 1 year, and the creation of nitrogen-efficient corn to enhance crop health and potential yield. These significant advancements in gene-editing are highlighted in our newly updated corporate presentation deck, which can be viewed [here].

About Origin Agritech Limited

Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company’s website at www.originagritech.com. The Company also maintains a Twitter account for updating investors on company and industry developments, which is @origin_agritech. 

Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the federal securities laws, including Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements address expected future business and financial performance and financial condition, and contain words like "expect," "anticipate," "intend," "plan," "believe," "seek," "will," "would," "target," and similar expressions and variations. Forward-looking statements address matters that are uncertain. Forward-looking statements are not guarantees of future performance and are based on assumptions and expectations which may not be realized. They are based on management’s current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates but involve a number of risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those discussed in forward-looking statements are: failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting our products; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; natural disasters and weather events and patterns; ability to protect and enforce the company’s intellectual property rights; and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty or obligation to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

For more information, please contact:

Origin Agritech Limited
Joe Ramelli
VP of Business Development
Phone: 310-845-6238
Email: joe@originagritech.com

Kate Lang (Mandarin/English)
Phone: +86 186-1839-3368
Email: [email protected]

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]

Source : Origin Agritech Unveils Rapid Gene-Editing Method and Nitrogen Efficient Corn in Updated Deck

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Initial evidence-based findings of three-year study strongly supports MiYOSMART portfolio

BANGKOK, Oct. 31, 2023 /PRNewswire/ — HOYA Vision Care, committed to developing innovative solutions to address the growing problem of myopia progression in children, extended its research to Europe in an effort to battle this global problem.

In the eye care industry, most research on childhood myopia is being conducted in East Asia, where the condition is most prevalent.1 With myopia increasing worldwide, there is a need to test the effectiveness of myopia management solutions in children of other ethnicities and geographic areas.1 To gather the needed data, the HOYA Global Medical Affairs team began conducting a three-year observational study in the United Kingdom (UK), with the goal of extending MiYOSMART benefits to European children with myopia. The study reached its one-year milestone earlier this year, with the results officially presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Conference held 23-27 April, in New Orleans.2 

The study involves 128 children aged 5 to 15 recruited at three university centres in the UK. All children were prescribed MiYOSMART spectacle lenses and their progress was followed, with the aim to evaluate the performance of MiYOSMART spectacle lenses in European children.2 T The results from this study demonstrated similar effectiveness of MiYOSMART spectacle lenses between European and Asian children, particularly in children aged 8 to 13 years .2, 3 Most children were symptom-free within one week, showing strong tolerability and acceptance.2 

"Childhood myopia is a widespread global concern, and our unwavering commitment to fighting this issue through innovative solutions like MiYOSMART spectacle lenses is stronger than ever. The interim results of our European research are encouraging," said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. "The comparable outcomes in the European cohort underscore that MiYOSMART represents an effective approach to slowing myopia progression in children, irrespective of their ethnicity. We look forward to sharing the results of this three-year study in the near future."

Over 2 million parents across the world have already trusted MiYOSMART, since its launch in 2018.4 

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of Myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.

About HOYA Vision Care

For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to Eye Care Professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.

References

Grzybowski A, Kanclerz P, Tsubota K, Lanca C, Saw SM. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol. 2020;20(1):27. McCullough S, Barr, H, Fulton, J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). ARVO 2023; 23-27 April 2023; New Orleans, LA, USA. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8. Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of July 2023.

Follow HOYA Vision Care on Linkedin

Source : HOYA Vision Care Releases One-Year MiYOSMART European Study Results

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

LOS ANGELES, Oct. 31, 2023 /PRNewswire/ — Ausom, a dedicated manufacturer and innovator of high-end off-road electric scooters, has just unveiled another flagship model, the Gallop, with dual motors, in the US market.

ausom gallop electric scooter

"We understand that thrill-seekers demand nothing less than the best." With this idea in mind, Ausom insists on creating high-performance mobility that brings more power and excitement to adventurers. After the launch of the Leopard in July, Ausom is now introducing Gallop, an even more powerful off-road beast.

Powered by two 1200W motors, the Ausom Gallop catapults you to a top speed of 41mph and conquers a 35% incline. Its 23.2Ah battery capacity effortlessly propels you on a 55-mile journey, while the dual charging ports ensure you’re back on the road in no time. By using 2 chargers simultaneously, it can be fully charged in just 6 hours. Brace yourself for an exhilarating and enduring adventure that leaves you breathless and stunned.

This beast features an SUV-inspired design, enhanced by two robust off-road tires with a 10-inch diameter and 3.15-inch width. These meticulously engineered tires are hard-wearing, impact-resistant, and fearless in challenging terrain.

Its rough double-sided swingarms deliver outstanding shock absorption, ensuring a smooth and comfortable ride even in rugged landscapes like no other.

Moreover, it’s built with an advanced braking system that comprises an e-brake and hydraulic disc brakes for increased precision, endurance and safety. The omnidirectional lighting system consists of 10 bright lights to guide you day and night.

The Gallop is now available on Ausom’s official website, Amazon, and Geekbuying. From 31st October, Ausom will be offering adventurers a special offer for the new launch. Order from the website or its partner platforms, and you can enjoy fast delivery, 14-day hassle-free returns and professional after-sales service. Grab a Gallop and  embark on an adrenaline-pumping journey.

About Ausom

The name "Ausom" is inspired by "Awesome", embodying the essence of creating nothing ordinary but awesome. Ausom was created by a group of adventurers and experts, and driven by their passion for exploration, igniting the spirit of adventure in everyone who experiences its off-road electric scooters. Anchored by three fundamental principles – product quality, eco-friendliness, and higher performance – Ausom forges ahead, proudly bringing a new wave of adventure to the middle high-end off-road electric scooter market.

For more information, visit Ausomstore.com.

Source : Ausom Unveils Gallop: Embracing the Super Power from a Dual-Motor Off-Road Electric Scooter

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network